Showing results (111-120 of 403) with videos related to
Sort By:
Pageof 41
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|February 11, 2018
Rare MYC-amplified Neuroblastoma With Large Cell HistologyRyosuke Matsuno, Andrew J Gifford, Junming Fang, et al.Cancer Research Communications|August 12, 2025
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid TumorsKenneth B DeSantes, Kimberly A McDowell, Paul M Sondel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium studyYael P Mossé, Emily Lipsitz, Elizabeth Fox, et al.Pediatric Blood & Cancer|January 25, 2020
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium reportE Anders Kolb, Peter J Houghton, Raushan T Kurmasheva, et al.Pediatric Blood & Cancer|June 29, 2010
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programChristopher L Morton, Peter J Houghton, E Anders Kolb, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical modelsMichael J Morowitz, Rosalind Barr, Qun Wang, et al.Journal of the National Cancer Institute|December 18, 2012
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survivalEric R Gamazon, Navin Pinto, Anuar Konkashbaev, et al.European Journal of Cancer (Oxford, England : 1990)|August 31, 2016
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidineKelly E Huibregtse, Kieuhoa T Vo, Steven G DuBois, et al.Cancer Chemotherapy and Pharmacology|January 2, 2010
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumorsElizabeth Fox, John M Maris, Susan L Cohn, et al.Cancer|April 20, 2023
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaKristina A Cole, Heba Ijaz, Lea F Surrey, et al.Pageof 41